Junshi Bio: EGFR exon 20 insertion and other rare mutation inhibitor JS111 was approved for trial
Teresa is approved in China for adjuvant treatment of patients with early-stage EGFR-mutant lung cancer
FDA accelerates approval of Johnson & Johnson's EGFR/c-Met dual antibody listing
The IPO application of Yifang Bioscience Innovation Board was accepted, the third-generation EGFR
Another domestic third-generation EGFR inhibitor applied for listing and CSPC obtained exclusive authorization
Betta Pharmaceuticals unveils the second-line Phase II clinical study data of the third-generation EGFR-TKI befortinib
The domestic competition for the third generation of EGFR-TKIs is fierce, and new drugs and generic drugs are successively reported for production
Missing became the first drug approved to treat NSCLC with EGFR exon 20 insertion mutation!
Takeda, Di Zhe, Zai Lab, and Yang Sen "compete on the same stage". Which EGFR exon20 inhibitor is better?
2021 ASCO targets lung cancer EGFR ex20ins, new drugs compete
Fuwo Pharmaceutical's fourth-generation EGFR small molecule targeted drug was approved for clinical use in China
ASCO2021: Patritumab Deruxtecan produces durable response in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer patients
Takeda reported the latest results of mobocertinib, further confirming the clinical benefits of patients with EGFR exon 20 insertion + mNSCLC
Br J Cancer: Anlotinib inhibits the angiogenesis of undifferentiated thyroid cancer by targeting EGFR
Prof. Lu Liqin: Whole-process management of EGFR mutation-positive NSCLC
-EGFR monoclonal antibody treatment-"Expert consensus on clinical management of skin adverse
Johnson & Johnson's EGFR/c-Met dual antibody, the first new drug for specific mutations in lung cancer, was approved by the FDA for marketing
EGFR 20ins ushered in the approval of the first targeted drug, and many new stars will be unveiled at 2021ASCO!
JTO: Durvalumab in the treatment of NSCLE patients with stage III EGFR mutations after concurrent radiotherapy and chemotherapy
Professor Cheng Ying: Osimitinib adjuvant treatment indications were approved, rewriting the domestic operable EGFR mutation treatment model